Scholarlink

Background and purpose <p>Sarcoma Viral Oncogene Homologue (KRAS) mutation status is a crucial biomarker in rectal cancer as KRAS mutations confer resistance to anti-EGFR targeted therapies and influence chemotherapy selection, affecting treatment decisions and prognosis. This study evaluates the efficacy of the hybrid intravoxel incoherent motion and diffusion kurtosis imaging (IVIM-DKI) model for non-invasive KRAS mutation identification in rectal cancer.</p> Methods <p>This prospective study included 73 patients with rectal cancer who underwent MRI scans using an IVIM-DKI sequence. KRAS mutation status was determined through histopathological analysis. The parameters derived from the hybrid IVIM-DKI model, including the apparent diffusion coefficient (ADC), true diffusion coefficient (D), diffusion kurtosis (K), perfusion fraction (f), and pseudo-diffusion coefficient (D*), were compared between the KRAS mutation group and wild-type group. The diagnostic performance was evaluated using the receiver operating characteristic (ROC) curve. The hybrid IVIM-DKI parameters and their association with clinicopathological features were also explored.</p> Results <p>Significant differences were observed between the KRAS mutation and wild-type groups for ADC, D, and K values (<i>p</i> &lt; 0.05). The K value derived from the IVIM-DKI model demonstrated the highest area under the ROC curve (AUC = 0.779) in characterizing KRAS mutation status, with a sensitivity of 88.1% and specificity of 70.3%. The ADC value also showed moderate diagnostic performance (AUC = 0.702). Specific IVIM-DKI parameters, such as f and K, were associated with various clinicopathological features, suggesting their potential as imaging biomarkers.</p> Conclusion <p>The hybrid IVIM-DKI model, particularly the diffusion kurtosis parameter, shows promise as a non-invasive imaging biomarker for KRAS mutation identification in rectal cancer. This approach may facilitate early detection of anti-EGFR therapy resistance, potentially guiding personalized treatment strategies and contributing to enhanced clinical outcomes.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Non-invasive identification of KRAS mutation in rectal cancer using hybrid intravoxel incoherent motion and diffusion kurtosis model

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月25日

查看全文
  • Jie Yuan,
  • Mingrong Yao,
  • Ziyuan Wang,
  • Wenli Tan,
  • Yun Zhang,
  • Huamei Yan,
  • Mengxiao Liu,
  • Kun Liu,
  • Hangjun Gong,
  • Songhua Zhan

摘要

Background and purpose

Sarcoma Viral Oncogene Homologue (KRAS) mutation status is a crucial biomarker in rectal cancer as KRAS mutations confer resistance to anti-EGFR targeted therapies and influence chemotherapy selection, affecting treatment decisions and prognosis. This study evaluates the efficacy of the hybrid intravoxel incoherent motion and diffusion kurtosis imaging (IVIM-DKI) model for non-invasive KRAS mutation identification in rectal cancer.

Methods

This prospective study included 73 patients with rectal cancer who underwent MRI scans using an IVIM-DKI sequence. KRAS mutation status was determined through histopathological analysis. The parameters derived from the hybrid IVIM-DKI model, including the apparent diffusion coefficient (ADC), true diffusion coefficient (D), diffusion kurtosis (K), perfusion fraction (f), and pseudo-diffusion coefficient (D*), were compared between the KRAS mutation group and wild-type group. The diagnostic performance was evaluated using the receiver operating characteristic (ROC) curve. The hybrid IVIM-DKI parameters and their association with clinicopathological features were also explored.

Results

Significant differences were observed between the KRAS mutation and wild-type groups for ADC, D, and K values (p < 0.05). The K value derived from the IVIM-DKI model demonstrated the highest area under the ROC curve (AUC = 0.779) in characterizing KRAS mutation status, with a sensitivity of 88.1% and specificity of 70.3%. The ADC value also showed moderate diagnostic performance (AUC = 0.702). Specific IVIM-DKI parameters, such as f and K, were associated with various clinicopathological features, suggesting their potential as imaging biomarkers.

Conclusion

The hybrid IVIM-DKI model, particularly the diffusion kurtosis parameter, shows promise as a non-invasive imaging biomarker for KRAS mutation identification in rectal cancer. This approach may facilitate early detection of anti-EGFR therapy resistance, potentially guiding personalized treatment strategies and contributing to enhanced clinical outcomes.